Ranbaxy could find buyers for its generic Lipitor rights, says analyst
This article was originally published in Scrip
Executive Summary
Is Ranbaxy Laboratories working on a Plan B aimed at relinquishing exclusivity rights for a generic version of Pfizer's Lipitor (atorvastatin) this November in the US , should it fail to resolve long-running regulatory issues with the US FDA on time?